BlueMountain Capital Management LLC Boosts Position in United Therapeutics Corporation (UTHR)
BlueMountain Capital Management LLC increased its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 88.3% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 18,916 shares of the biotechnology company’s stock after purchasing an additional 8,872 shares during the quarter. BlueMountain Capital Management LLC’s holdings in United Therapeutics Corporation were worth $2,454,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Amalgamated Bank increased its stake in United Therapeutics Corporation by 24.0% during the 2nd quarter. Amalgamated Bank now owns 8,708 shares of the biotechnology company’s stock worth $1,130,000 after purchasing an additional 1,683 shares in the last quarter. BlackRock Inc. increased its stake in United Therapeutics Corporation by 3.3% during the 2nd quarter. BlackRock Inc. now owns 4,897,334 shares of the biotechnology company’s stock worth $635,330,000 after purchasing an additional 155,349 shares in the last quarter. Nationwide Fund Advisors increased its stake in United Therapeutics Corporation by 10.5% during the 2nd quarter. Nationwide Fund Advisors now owns 121,454 shares of the biotechnology company’s stock worth $15,756,000 after purchasing an additional 11,586 shares in the last quarter. Captrust Financial Advisors bought a new stake in United Therapeutics Corporation during the 2nd quarter worth approximately $925,000. Finally, Bridgewater Associates LP increased its stake in United Therapeutics Corporation by 27.3% during the 2nd quarter. Bridgewater Associates LP now owns 73,968 shares of the biotechnology company’s stock worth $9,596,000 after purchasing an additional 15,876 shares in the last quarter.
A number of analysts recently issued reports on UTHR shares. ValuEngine cut United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 2nd. BidaskClub raised United Therapeutics Corporation from a “sell” rating to a “hold” rating in a research report on Friday, June 16th. Jefferies Group LLC reaffirmed a “sell” rating and set a $105.00 price target on shares of United Therapeutics Corporation in a research report on Thursday, June 8th. UBS AG reaffirmed a “sell” rating and set a $106.00 price target on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. Finally, Zacks Investment Research downgraded United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Six equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $134.50.
In other news, Director Raymond Dwek sold 3,490 shares of the company’s stock in a transaction on Friday, June 23rd. The stock was sold at an average price of $131.71, for a total transaction of $459,667.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 1,237 shares of the company’s stock in a transaction on Thursday, June 29th. The shares were sold at an average price of $130.92, for a total value of $161,948.04. Following the transaction, the chief executive officer now directly owns 1,377 shares in the company, valued at approximately $180,276.84. The disclosure for this sale can be found here. In the last three months, insiders sold 25,198 shares of company stock worth $3,281,816. Insiders own 7.80% of the company’s stock.
Shares of United Therapeutics Corporation (NASDAQ:UTHR) opened at 120.79 on Monday. United Therapeutics Corporation has a one year low of $110.90 and a one year high of $169.89. The firm’s 50-day moving average price is $128.92 and its 200 day moving average price is $129.77. The firm has a market cap of $5.25 billion, a P/E ratio of 14.01 and a beta of 1.52.
United Therapeutics Corporation (NASDAQ:UTHR) last announced its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.61 by ($4.86). United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The company had revenue of $444.60 million for the quarter, compared to the consensus estimate of $391.53 million. During the same quarter last year, the company posted $4.42 EPS. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. Analysts predict that United Therapeutics Corporation will post $10.09 EPS for the current year.
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.